[go: up one dir, main page]

WO2008137075A3 - Compositions and methods for the treatment of metabolic disorders and inflammation - Google Patents

Compositions and methods for the treatment of metabolic disorders and inflammation Download PDF

Info

Publication number
WO2008137075A3
WO2008137075A3 PCT/US2008/005686 US2008005686W WO2008137075A3 WO 2008137075 A3 WO2008137075 A3 WO 2008137075A3 US 2008005686 W US2008005686 W US 2008005686W WO 2008137075 A3 WO2008137075 A3 WO 2008137075A3
Authority
WO
WIPO (PCT)
Prior art keywords
stamp2
agents
inflammation
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/005686
Other languages
French (fr)
Other versions
WO2008137075A2 (en
Inventor
Gokhan S Hotamisligil
Kathryn E Wellen
Fahri Saatcioglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2008137075A2 publication Critical patent/WO2008137075A2/en
Publication of WO2008137075A3 publication Critical patent/WO2008137075A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the discovery of the role of STAMP2 in coordination of responses to both inflammatory and nutritional stimuli. The invention provides for the use of STAMP2 deficient cells and STAMP2 deficient mice for screening for agents to modulate biomarkers associated with inflammation, oxidative stress, and metabolism. The invention also provides for the use of STAMP containing cells, particularly adipose, hepatic, or muscle cells, to identify agents that modulate STAMP2. The invention provide agents identified by the methods of the invention and their use as therapeutic agents for the treatment of metabolic disorders, which frequently include an inflammatory component. The invention also provide kits including STAMP 2 deficient cells.
PCT/US2008/005686 2007-05-02 2008-05-02 Compositions and methods for the treatment of metabolic disorders and inflammation Ceased WO2008137075A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92739807P 2007-05-02 2007-05-02
US60/927,398 2007-05-02

Publications (2)

Publication Number Publication Date
WO2008137075A2 WO2008137075A2 (en) 2008-11-13
WO2008137075A3 true WO2008137075A3 (en) 2008-12-31

Family

ID=39791411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005686 Ceased WO2008137075A2 (en) 2007-05-02 2008-05-02 Compositions and methods for the treatment of metabolic disorders and inflammation

Country Status (1)

Country Link
WO (1) WO2008137075A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9928345B2 (en) * 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
KR101809605B1 (en) 2016-05-12 2017-12-15 연세대학교 원주산학협력단 Method for diagnosis of oxidative stress related disease using enzymes having circadian rhythms
US12263252B2 (en) * 2019-06-05 2025-04-01 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
CN114586735B (en) * 2020-12-04 2024-02-09 南京大学 Construction and application of Pparg gene site-directed mutagenesis mouse model

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259104A1 (en) * 2002-10-22 2004-12-23 Lamberts Steven Willem Jan Test
WO2005114216A2 (en) * 2005-02-22 2005-12-01 Biomedisinsk Innovasjon As Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2006063213A2 (en) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Serum amyloid a protein in inflammation and obesity
US20070015246A1 (en) * 2000-03-24 2007-01-18 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1980148A1 (en) * 2006-01-31 2008-10-15 Takeda Pharmaceutical Company Limited Genetically modified animal and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015246A1 (en) * 2000-03-24 2007-01-18 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20040259104A1 (en) * 2002-10-22 2004-12-23 Lamberts Steven Willem Jan Test
WO2006063213A2 (en) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Serum amyloid a protein in inflammation and obesity
WO2005114216A2 (en) * 2005-02-22 2005-12-01 Biomedisinsk Innovasjon As Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
EP1980148A1 (en) * 2006-01-31 2008-10-15 Takeda Pharmaceutical Company Limited Genetically modified animal and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WELLEN KATHRYN E ET AL: "Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis.", CELL 4 MAY 2007, vol. 129, no. 3, 4 May 2007 (2007-05-04), pages 537 - 548, XP002500391, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2008137075A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
Niki Assessment of antioxidant capacity in vitro and in vivo
WO2010132479A3 (en) Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
WO2009059150A3 (en) Biomarkers for fatty liver disease and methods using the same
WO2008137075A3 (en) Compositions and methods for the treatment of metabolic disorders and inflammation
WO2010062863A3 (en) Compositions containing satiogens and methods of use
MX2009008099A (en) Compounds for the prevention and treatment of cardiovascular diseases.
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
IL191293A0 (en) Compositions for regulating metabolic disorders and methods of use thereof
TW200716140A (en) Treatment of inflammatory conditions
CL2008003407A1 (en) Substituted heterobicyclo aryl- and heteroarylcarbonyl derivative compounds; pharmaceutical composition; preparation procedure; and its use in the treatment and / or prevention of metabolic disorders, mediated by the inhibition of the enzyme hsd-1.
EP1804660A4 (en) System and methods for assessing the neuromuscular pathway prior to nerve testing
MX380755B (en) PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JANUS KINASE 1 (JAK1) INHIBITORS.
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
EP3822352A3 (en) Methods and compositions for modulating apolipoprotein(a) expression
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
WO2012067970A3 (en) Transcriptional repression leading to parkinson's disease
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
PH12014502286B1 (en) Improving resistance to skeletal muscle fatigue
WO2009055001A3 (en) Methods of treating aging and methods of screening candidate agents therefor
WO2010048710A8 (en) Neurotoxic sterol glycosides
WO2009098355A8 (en) Novel use of probiotics
WO2008042469A3 (en) Knockout mice for different genes and their use for gene characterizatio
WO2007084861A3 (en) Xenohormesis based compositions and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754200

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08754200

Country of ref document: EP

Kind code of ref document: A2